ADELAIDE, Australia, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global contract research organization focused on accelerating clinical development for biotech sponsors, today announced the ...
Clinical trial findings showed Avance was noninferior to a collagen nerve cuff for returning sensory function in patients with nerve injuries in the hand. The Food and Drug Administration (FDA) has ...
Avance Biosciences has opened a 75,000-square-foot biomanufacturing facility in Northwest Houston. The facility will support the production of cell and gene therapies, vaccines, and other biologic ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The 75,000-square-foot building ...
(RTTNews) - Axogen, Inc. (AXGN) announced that the U.S. Food and Drug Administration has approved the Biologics License Application (BLA) for AVANCE, an acellular nerve allograft (arwx). AXGN closed ...
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of ...
The U.S. FDA granted accelerated approval for the Biologics License Application for Axogen Inc.'s Avance, an acellular nerve allograft that serves as a scaffold for nerve regrowth, for treatment of ...
Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...
Dec 3 (Reuters) - The U.S. Food and Drug Administration has approved Axogen's (AXGN.O), opens new tab nerve repair graft, the health regulator said on Wednesday, paving the way for 12 years of ...
Barchemy founder and CEO Larry Toscano will retain a significant ownership stake and continue to lead the company Barchemy was founded in 2015 Avance Investment Management has made an investment in ...
A good sum of two good parts. Our research team assigns Silver ratings to strategies that they have a high conviction will outperform the relevant index, or most peers, over a market cycle on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results